Ya-Chi Chen
Chief Scientific Officer OBI Pharma
Dr. Ya-Chi Chen is the Chief Scientific Officer at OBI Pharma. She holds a Doctor of Pharmacy degree from the University of Iowa and brings over 20 years of experience in drug development, specializing in clinical pharmacology and translational medicine. Her expertise covers small molecules, biologics, and antibody-drug conjugates across virology, immunology, and oncology.
A passionate advocate of science-driven, model-informed drug development (MIDD), Dr. Chen leverages translational insights and cross-functional collaboration to accelerate development and improve patient outcomes. She has held senior leadership positions at leading biopharmaceutical companies, including Executive Director at Revolution Medicines, Senior Director at Gilead Sciences, and Director at Roche.
Seminars
- Explaining how bispecific ADCs improve efficacy by engaging two antigens, reducing the risk of escape from antigen loss or tumour heterogeneity
- Pursuing a “Two-Hit” Approach: Combining complementary payloads (e.g., DNA-damaging + DDRi) to deliver a “two-hit” attack, heightening tumour kill and resistance barriers
- Optimising bispecific ADC dual binding to improve tumour specificity, internalisation, and safety by balancing antigen engagement
